Through the collaboration, Campbell University’s experts in pharmaceutical product development will initiate a program to develop a novel formulation for ear infections in children.
Jarrett Disbrow, president and CEO of Arbor Pharmaceuticals, said: “Arbor is pleased to be working with Campbell’s Pharmaceutical Sciences Institute on this important product development project. By initiating this development work on our second product, Arbor continues to expand our pediatric product portfolio aimed at treating the most common childhood illnesses.”
Dr William Stagner, director of Campbell University’s Pharmaceutical Sciences Institute, commented: “This pharmaceutical development project will leverage Campbell’s unique in-house expertise and deliver real clinical value in assisting this growing specialty pharmaceutical company. Campbell is glad to have Arbor as a partner, and we look forward to bringing our collective industry and academic experiences to Arbor Pharmaceuticals as they bring another therapy to market.”